PADI4/PAD4 Recombinant Protein | PADI4 recombinant protein

PADI4/PAD4 Protein, Human, Recombinant (His Tag)

Cat. Num. AAA8120670

• Purity: >95% as determined by SDS-PAGE
• Synonyms: PADI4/PAD4; PADI4/PAD4 Protein; Human; Recombinant (His Tag); Human PAD4/PADI4 Protein (His Tag); PAD Protein; PAD4 Protein; PADI5 Protein; PDI4 Protein; PDI5 Protein; peptidyl arginine deiminase; type IV; PADI4 recombinant protein

• Host: Baculovirus-Insect Cells
• Purity/Purification: >95% as determined by SDS-PAGE
• Form/Format: Lyophilized from sterile 20mM Tris, 500mM NaCl, 10% glycerol, pH7.4. Normally 5%-8% trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
• Sequence: Met1-Pro663

• Species: Human
• Endotoxin: <1.0EU per ug protein as determined by the LAL method.
• Predicted N Terminal: Met
• Tag: N-His
• Protein Construction: A DNA sequence encoding the human PADI4 (Met1-Pro663) was expressed with a polyhistidine tag at the N-terminus.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
• Preparation and Storage: Samples are stable for up to twelve months from date of receipt at -20 degree C to -80 degree C. Store it under sterile conditions at -20 degree C to -80 degree C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.; In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid.; They are shipped out with blue ice.

SDS-Page

Related Product Information for PADI4 recombinant protein

Background: Protein-arginine deiminase type-4, also known as HL-6 PAD, Peptidylarginine deiminase IV, Protein-arginine deiminase type I V and PADI4, is a cytoplasm and nucleus protein that belongs to the protein arginine deiminase family. PADI4 is expressed in CD34⁺ stem cells in normal tissues, and many more CD34+ cells expressing PADI4 are present in tumour tissues. PADI4 post-translationally converts peptidylarginine to citrulline, a process called citrullination. Studies have demonstrated the high expression of PADI4 in various malignant tumor tissues. PADI4 is also expressed at high levels in the blood of patients with some malignant tumors. Citrullination of histone, cytokeratin, antithrombin and fibronectin have been confirmed to be involved in abnormal apoptosis, high coagulation, and disordered cell proliferation and differentiation, all of which are main features of malignant tumors. PADI4 may play an important role in tumorigenesis. Genetic variations in PADI4 are a cause of susceptibility to rheumatoid arthritis (RA). It is a systemic inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures.

References

Nakashima K. et al.,1999, J. Biol. Chem. 274: 27786-92. Suzuki A. et al., 2003, Nat. Genet. 34:395-402. Nakayama-Hamada M. et al., 2005, Biochem. Biophys. Res. Commun. 327:192-200. Chang, X. et al., 2010, Cancer Cell Int 10:7.